WhaleCreep

Avidity Partners Management LP 13F holdings, Q2 2020

Hedge fundSEC filingsCompare with another fundHoldings as of 2020-06-30, filed 2020-08-14

Avidity Partners Management LP disclosed 57 US equity positions worth $1.6bn in its Q2 2020 13F filing. Its largest position is ABBV at 9.7% of the reported book, followed by REGN and BIOHAVEN PHARMACTL HLDG CO L. Versus Q1 2020 it opened 33 new positions, added to 20, reduced 4 and exited 25.

$1.6bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
57
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
9.7%
Largest position
The largest single position as a share of the reported equity book.
45.0%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
31
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2020: 33 new, 20 added, 4 reduced, 25 exited

50 of 57
ABBV ABBVIE INCHealthcare9.7%$152m1.55m+224%added
REGN REGENERON PHARMACEUTICALSHealthcare5.3%$82.4m132,100+164%added
BIOHAVEN PHARMACTL HLDG CO L no ticker–5.2%$80.8m1.10m+105%added
BAX BAXTER INTL INCHealthcare4.4%$69.0m800,900–new
IMMU IMMUNOMEDICS INC–4.3%$67.7m1.91m+288%added
EXEL EXELIXIS INCHealthcare4.1%$64.0m2.69m+148%added
ALXN ALEXION PHARMACEUTICALS INC–3.7%$57.0m507,700+217%added
HO1 HOLOGIC INC–3.0%$46.6m817,200–new
SGENEUR SEATTLE GENETICS INC–2.7%$42.6m250,900−57%reduced
AUPH AURINIA PHARMACEUTICALS INCHealthcare2.6%$40.2m2.47m+109%added
MNTA MOMENTA PHARMACEUTICALS INC–2.5%$38.3m1.15m+47%added
CCXIEUR CHEMOCENTRYX INC–2.4%$37.2m645,800+174%added
ARVN ARVINAS INCHealthcare2.3%$36.1m1.08m–new
AXSM AXSOME THERAPEUTICS INC.Healthcare2.1%$33.3m404,900+106%added
KDMN KADMON HLDGS INC–2.1%$32.9m6.43m+127%added
PRNB PRINCIPIA BIOPHARMA INC–2.1%$32.8m548,500–new
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare2.1%$32.4m674,487–new
HORIZON THERAPEUTICS PUB L no ticker–1.9%$29.8m536,200+61%added
ESPREUR ESPERION THERAPEUTICS INC NE–1.8%$28.7m559,700+173%added
AVTR AVANTOR INCHealthcare1.8%$27.4m1.61m–new
VIR VIR BIOTECHNOLOGY INCHealthcare1.6%$25.4m620,600–new
MERSANA THERAPEUTICS INC no ticker–1.6%$25.0m1.07m–new
DVAX DYNAVAX TECHNOLOGIES CORP–1.5%$23.7m2.67m−30%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare1.5%$22.6m1.53m–new
NBIX NEUROCRINE BIOSCIENCES INCHealthcare1.4%$22.6m185,100+89%added
8IN SYNEOS HEALTH INC–1.4%$21.3m366,500–new
BRISTOL-MYERS SQUIBB CO no ticker–1.3%$20.7m5.79m–new
BTAI BIOXCEL THERAPEUTICS INC–1.3%$20.6m388,095+84%added
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare1.3%$20.3m738,547–new
CRSP CRISPR THERAPEUTICS AGHealthcare1.3%$20.2m274,300–new
HARPOON THERAPEUTICS INC no ticker–1.3%$20.0m1.21m–new
MCK MCKESSON CORPHealthcare1.3%$19.6m128,000−47%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare1.2%$18.9m1.33m–new
CHRS COHERUS ONCOLOGY INCHealthcare1.2%$18.3m1.02m+168%added
EDIT EDITAS MEDICINE INCHealthcare1.1%$17.7m600,000–new
ASND ASCENDIS PHARMA A/SHealthcare1.1%$17.6m118,900+98%added
AZN ASTRAZENECA PLCHealthcare1.1%$17.2m325,990–new
ALEC ALECTOR INCHealthcare1.1%$16.8m686,400−3.9%reduced
MDT Medtronic PlcHealthcare1.0%$15.9m173,700–new
PREVAIL THERAPEUTICS INC no ticker–1.0%$15.3m1.03m–new
RCUS ARCUS BIOSCIENCES INCHealthcare0.9%$14.6m589,000–new
ADAPY ADAPTIMMUNE THERAPEUTICS PLCHealthcare0.9%$14.4m1.44m–new
ANIK ANIKA THERAPEUTICS INCHealthcare0.9%$13.7m362,490+116%added
RPRX ROYALTY PHARMA PLCHealthcare0.6%$9.7m200,000–new
SURFUSD SURFACE ONCOLOGY INC–0.6%$9.7m1.48m–new
DCPHEUR DECIPHERA PHARMACEUTICALS IN–0.6%$9.3m156,266–new
NTLA INTELLIA THERAPEUTICS INCHealthcare0.6%$8.8m418,178–new
VSTM VERASTEM INCHealthcare0.5%$7.6m4.41m+58%added
1LIFE HEALTHCARE INC no ticker–0.5%$7.3m200,000–new
AKOUOS INC no ticker–0.5%$7.1m315,000–new

Exited since Q1 2020

25 rows
MRK MERCK & CO. INC5.4%$37.9m
BMRN BIOMARIN PHARMACEUTICAL INC3.7%$25.5m
CAH CARDINAL HEALTH INC3.5%$24.2m
MRTXEUR MIRATI THERAPEUTICS INC3.3%$22.7m
CTLTEUR CATALENT INC3.1%$21.4m
BIIB BIOGEN INC2.8%$19.6m
CVS CVS HEALTH CORP2.4%$16.4m
ACAD ACADIA PHARMACEUTICALS INC2.2%$15.1m
GILD GILEAD SCIENCES INC2.1%$15.0m
XLRN ACCELERON PHARMA INC2.1%$14.9m
CI THE CIGNA GROUP1.7%$11.5m
UNIQURE NV no ticker1.6%$11.2m
MRNA MODERNA INC1.6%$10.9m
HUM HUMANA INC1.5%$10.4m
VRTX VERTEX PHARMACEUTICALS INC1.2%$8.1m
SRPT SAREPTA THERAPEUTICS INC1.1%$7.8m
LGND LIGAND PHARMACEUTICALS INC1.1%$7.4m
IRWD IRONWOOD PHARMACEUTICALS INC1.1%$7.4m
CRL CHARLES RIV LABS INTL INC1.0%$7.2m
ALLERGAN PLC no ticker1.0%$7.1m
AERIEUR AERIE PHARMACEUTICALS INC1.0%$6.8m
AIMT AIMMUNE THERAPEUTICS INC0.8%$5.9m
NERV MINERVA NEUROSCIENCES INC0.4%$2.7m
SNSSEUR SUNESIS PHARMACEUTICALS INC0.3%$1.8m
COLL COLLEGIUM PHARMACEUTICAL INC0.04%$278k

Sector mix

  • Healthcare55.3%
  • Unclassified44.7%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters